Novel approaches to developing new antibiotics for bacterial infections

British Journal of Pharmacology

Volumn 152, Issue 8, 2007, Pages 1147-1154

  Coates, A R M ^a   Hu, Y ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antibiotic resistance; Bacterial infections; Bacteriophages; Genomics; Multiplying bacteria; Non culturable bacteria; Non multiplying bacteria; Novel antibiotics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CLAVULANIC ACID; ISONIAZID; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMIDOCHRYSOIDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIOPHAGE; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; GENOMICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; GENOMICS; HUMANS;

EID: 36949030717     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707432     Document Type: Review

References (113)

1. Abraham EP (1987). Cephalosporins 1945-86. In: Williams, JD (ed). The Cephalosporins. Adis Press: Auckland. pp 1-14.
2. Alestig K, Hogevik H, Olaison L (2000). Infective endocarditis: a diagnostic and therapeutic challenge for the new millennium. Scand J Infect Dis 32: 343-356.
3. Apfel CM, Locher H, Evers S, Takacs B, Hubschwerlen C, Pirson W et al. (2001). Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob Agents Chemother 45: 1058-1064.
4. Arcus VL, Lott JS, Johnston JM, Baker EN (2006). The potential impact of structural genomics on tuberculosis drug discovery. Drug Discov Today 11: 28-34.
5. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S (2004). Bacterial persistence as a phenotypic switch. Science 305: 1622-1625.
6. Ball AP, Bartlett JG, Craig WA, Drusano GL, Felmingham D, Garau JA et al. (2004). Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC. J Chemother 16: 419-436.
7. Barbachyn MR, Ford CW (2003). Structure-activity relationships leading to linezolid. Angew Chem Int Ed Engl 42: 2010-2023.
8. Bax RP, Mullan N (1999). Response of the pharmaceutical industry to antimicrobial resistance. Balliere Clin Infect Dis 5: 289-304.
9. Bax RP, Anderson R, Crew J, Fletcher P, Johnson T, Kaplan E et al. (1998). Antibiotic resistance - what can we do? Nat Med 4: 545-546.
10. Becker D, Selbach M, Rollenhagen C, Ballmaier M, Meyer TF, Mann M et al. (2006). Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 440: 303-307.
11. Beenken KE, Dunman PM, McAleese F, Macapagal D, Murphy E, Projan SJ et al. (2004). Global gene expression in Staphylococcus aureus biofilms. J Bacteriol 186: 4665-4684.
12. Bernhardt TG, Wang IN, Struck DK, Young R (2001). A protein antibiotic in the phage Qbeta virion: diversity in lysis targets. Science 292: 2326-2329.
13. Black MT, Hodgson J (2005). Novel target sites in bacteria for overcoming antibiotic resistance. Adv Drug Deliv Rev 57: 1528-1538.
14. Borysowski J, Weber-Dabrowska B, Gorski A (2006). Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med (Maywood) 231: 366-377.
15. Bradley JS, Guidos R, Baragona S, Bartlett JG, Rubinstein E, Zhanel GG et al. (2007). Anti-infective research and development - problems, challenges, and solutions. Lancet Infect Dis 7: 68-78.
16. Bugg TD, Lloyd AJ, Roper DI (2006). Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord Drug Targets 6: 85-106.
17. Clements JM, Ayscough A, Keavey K, East SP (2002). Peptide deformylase inhibitors, potential for a new class of broad spectrum antibacterials. Curr Med Chem 1: 239-249.
18. Coates AR, Hu Y (2006). New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Drugs R D 7: 133-151.
19. Coates A, Hu Y, Bax R, Page C (2002). The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 1: 895-910.
20. Cohen R, Green M (2004). Resistance trends in Streptococcus pyogenes (PROTEKT years 1-3 [1999-2002]). J Chemother 6: 71-82.
21. Costerton JW, Stewart PS, Greenberg EP (1999). Bacterial biofilms: a common cause of persistent infections. Science 284: 1318-1322.
22. Cottagnoud P, Johnson M, Cottagnoud M, Piddock L (2005). Preincubation of pneumococci with beta-lactams alone or combined with levofloxacin prevents quinolone-induced resistance without increasing intracellular levels of levofloxacin. Antimicrob Agents Chemother 49: 3517-3519.
23. Craig M, McCready TL, Luu HA, Smillie MA, Dubord P, Holmes CF (1993). Identification and characterization of hydrophobic microcystins in Canadian freshwater cyanobacteria. Toxicon 31: 1541-1549.
24. Dabrowska K, Switala-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A (2005). Bacteriophage penetration in vertebrates. J Appl Microbiol 98: 7-13.
25. Dagan R, Klugman KP, Craig WA, Baquero F (2001). Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 47: 129-140.
26. Diaz-Torres ML, Villedieu A, Hunt N, McNab R, Spratt DA, Allan E et al. (2006). Determining the antibiotic resistance potential of the indigenous oralmicrobiota of humans using a metagenomic approach. FEMS Microbiol Lett 258: 257-262.
27. Dougherty TJ, Miller PF (2006). Microbial genomics and drug discovery: exploring innovative routes of drug discovery in the postgenomic era. IDrugs 9: 420-422.
28. Dougherty TJ, Barrett JF, Pucci MJ (2003). Genomics-based approaches to novel antimicrobial target discovery. In: Dougherty TJ, Projan SJ (eds). Microbial Genomics and Drug Discovery. Marcel Dekker: New York. pp 71-96.
29. Doyle MP, Erickson MC (2006). Reducing the carriage of foodborne pathogens in livestock and poultry. Poult Sci 85: 960-973.
30. Elliott TS, Foweraker J, Gould FK, Perry JD, Sandoe JA, Working Party of the British Society for Antimicrobial Chemotherapy (2004). Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 54: 971-981.
31. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P (2005). Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 49: 4789-4792.
32. Epstein BJ, Gums JG, Drlica K (2004). The changing face of antibiotic prescribing: the mutant selection window. Ann Pharmacother 38: 1675-1682.
33. Fernandez P (2006). Antibacterial discovery and development-the failure of success? Nat Biotechnol 24: 1497-1503.
34. Field D, Hughes J, Moxon ER (2004). Using the genome to understand pathogenicity. Methods Mol Biol 266: 261-287.
35. Finch R (2006). Gram-positive infections: lessons learnt and novel solutions. Clin Microbiol Infect 12 (Suppl 8): 3-8.
36. Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH (2006). Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 58: 1185-1192.
37. Fischetti VA, Nelson D, Schuch R (2006). Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 24: 1508-1511.
38. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR et al. (1995). Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269: 496-512.
39. Fleming A (1929). On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 10: 226.
40. Ford CW, Zurenko GE, Barbachyn MR (2001). The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord 1: 181-199.
41. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L et al. (2006). Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2: e7.
42. Fox JL (2006). The business of developing antibacterials. Nat Biotechnol 24: 1521-1528.
43. Freiberg C, Brotz-Oesterhelt H (2005). Functional genomics in antibacterial drug discovery. Drug Discov Today 10: 927-935.
44. Fux CA, Costerton JW, Stewart PS, Stoodley P (2005). Survival strategies of infectious biofilms. Trends Microbiol 13: 34-40.
45. Galli J, Ardito F, Calo L, Mancinelli L, Imperiali M, Parrilla C et al. (2006). Recurrent upper airway infections and bacterial biofilms. J Laryngol Otol 3: 1-4.
46. Garcia MH, Ivanova N, Kunin V, Warnecke F, Barry KW, McHardy AC et al. (2006). Metagenomic analysis of two enhanced biological phosphorus removal (EBPR) sludge communities. Nat Biotechnol 24: 1263-1269.
47. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroedan F et al. (1998). Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279: 365-370.
48. Hancock REW (2007). The end of an era? Nat Rev Drug Discov 6: 28.
49. Haney SA, Alkane LE, Dunman PM, Murphy E, Projan SJ (2002). Genomics in anti-infective drug discovery-getting to endgame. Curr Pharmaceut Des 8: 1099-1118.
50. Hendrix RW (2002). Bacteriophages: evolution of the majority. Theor Popul Biol 61: 471-480.
51. Hu YM, Butcher PD, Sole K, Mitchison DA, Coates AR (1998). Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett 158: 139-145.
52. Hu Y, Coates AR (1999). Transcription of two sigma 70 homologue genes, sigA and sigB, in stationary-phase Mycobacterium tuberculosis. J Bacteriol 181: 469-476.
53. Hu Y, Coates AR, Mitchison DA (2003). Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 653-657.
54. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM (2003). Bacteriophage treatment of a severe Escherichia coli respiratory infection in broiler chickens. Avian Dis 47: 1399-1405.
55. Johansen J, Rasmussen AA, Overgaard M, Valentin-Hansen P (2006). Conserved small non-coding RNAs that belong to the sigmaE regulon: role in down-regulation of outer membrane proteins. J Mol Biol 364: 1-8.
56. Jones BV, Marchesi JR (2007). Transposon-aided capture (TRACA) of plasmids resident in the human gut mobile metagenome. Nat Methods 4: 55-61.
57. Karchmer AW (2004). Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin Infect Dis 39 (suppl 3): S142-S150.
58. Kardas P, Devine S, Golembesky A, Roberts C (2005). A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents 26: 106-113.
59. Kern WV (2006). Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Int J Clin Pract 60: 370-378.
60. Lee DG, Jeon JH, Jang MK, Kim NY, Lee JH, Lee JH et al. (2007). Screening and characterization of a novel fibrinolytic metalloprotease from a metagenomic library. Biotechnol Lett 29: 465-472.
61. Lewis K (2007). Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5: 48-56.
62. Lewis K, Ausubel FM (2006). Prospects for plant-derived antibacterials. Nat Biotechnol 24: 1504-1507.
63. Li XZ (2005). Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms. Int J Antimicrob Agents 25: 453-463.
64. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
65. Liu J, Dehbi M, Moeck G, Arhin F, Bauda P, Bergeron D et al. (2004). Antimicrobial drug discovery through bacteriophage genomics. Nat Biotechnol 22: 185-191.
66. Loeffler JM, Nelson D, Fischetti VA (2001). Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294: 2170-2172.
67. Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen D, Yuan Z et al. (2000). Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother 44: 1825-1831.
68. Matsuda T, Freeman TA, Hilbert DW, Duff M, Fuortes M, Stapleton PP et al. (2005). Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137: 639-646.
69. McDevitt D, Rosenberg M (2001). Exploiting genomics to discover new antibiotics. Trends Microbiol 9: 611-617.
70. Metlay JP, Powers JH, Dudley MN, Christiansen K, Finch RG (2006). Antimicrobial drug resistance, regulation, and research. Emerg Infect Dis 12: 183-190.
71. Mills SD (2006). When will the genomics investment pay off for antibacterial discovery? Biochem Pharmacol 71: 1096-1102.
72. Mitchison DA (1998). How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2: 10-15.
73. Mitchison DA (2005). The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 171: 699-706.
74. Monaghan RL, Barrett JF (2006). Antibacterial drug discovery - then, now and the genomics future. Biochem Pharmacol 71: 901-909.
75. Murray CJ (1991). Social, economic and operational research on tuberculosis: recent studies and some priority questions. Bull Int Union Tuberc Lung Dis 66: 149-156.
76. Nakai T, Park SC (2002). Bacteriophage therapy of infectious diseases in aquaculture. Res Microbiol 153: 13-18.
77. Nelson D, Loomis L, Fischetti VA (1997). Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 98: 4107-4112.
78. Niederman MS (2005). Principles of appropriate antibiotic use. Int J Antimicrob Agents 26 (Suppl 3): S170-S175.
79. Norrby SR, Nord CE, Finch R, European Society of Clinical Microbiology and Infectious Diseases (2005). Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 5: 115-119.
80. Ono A, Miyazaki R, Sota M, Ohtsubo Y, Nagata Y, Tsuda M (2007). Isolation and characterization of naphthalene-catabolic genes and plasmids from oil-contaminated soil by using two cultivation - independent approaches. Appl Microbiol Biotechnol 74: 501-510.
81. Paterson DL (2006). The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 (Suppl 2): S43-S48.
82. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007). Drugs for bad bugs: confronting the challenges of antibacterial drug discovery. Nat Rev Drug Discov 6: 29-40.
83. Pelaez F (2006). The historical delivery of antibiotics from microbial natural products - can history repeat? Biochem Pharmacol 71: 981-990.
84. Polissi A, Soria MR (2005). Functional genomics of bacterial pathogens: from post-genomics to therapeutic targets. Mol Microbiol 57: 307-312.
85. Projan SJ, Shlaes DM (2004). Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect 10: 18-22.
86. Pucci MJ (2006). Use of genomics to select antibacterial targets. Biochem Pharmacol 71: 1066-1072.
87. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, BSAC Extended Working Party on Bacteraemia Resistance Surveillance (2004). Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 53: 1018-1032.
88. Rolinson GN (1982). The history and background of Augmentin. S Afr Med J 28: 3A-4A.
89. Rolinson GN, Geddes AM (2007). The 50th anniversary of the discovery of 6-aminopenicillanic acid (6-APA). Int J Antimicrob Agents 29: 3-8.
90. Rondon MR, August PR, Bettermann AD, Brady SF, Grossman TH, Liles MR et al. (2000). Cloning the soil metagenome: a strategy for accessing the genetic and functional diversity of uncultured microorganisms. Appl Environ Microbiol 66: 2541-2547.
91. Saidijam M, Benedetti G, Ren Q, Xu Z, Hoyle CJ, Palmer SL et al. (2006). Microbial drug efflux proteins of the major facilitator superfamily. Curr Drug Targets 7: 793-811.
92. Sakharkar KR, Sakharkar MK, Chow VT (2004). A novel genomics approach for the identification of drug targets in pathogens, with special reference to Pseudomonas aeruginosa. In Silico Biol 4: 355-360.
93. Schmid MB (2006a). Crystallizing new approaches for antimicrobial drug discovery. Biochem Pharmacol 71: 1048-1056.
94. Schmid MB (2006b). Do targets limit antibiotic discovery? Nat Biotechnol 24: 419-420.
95. Sheng H, Knecht HJ, Kudva IT, Hovde CJ (2006). Application of bacteriophages to control intestinal Escherichia coli O157:H7 levels in ruminants. Appl Environ Microbiol 72: 5359-5366.
96. Sheridan C (2006). Antibiotics au naturel. Nat Biotechnol 24: 1494-1496.
97. Smith AW, Brown MRW (2003). Biofilms, dormancy and resistance. In: Coates ARM (ed). Dormancy and Low-Growth States in Microbial Disease - Advances in Molecular and Cellular Microbiology pp 161-179. Cambridge University Press: Cambridge, UK.
98. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards Jr JE (2004). Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38: 1279-1286.
99. Spratt BG (1994). Resistance to antibiotics mediated by target alterations. Science 264: 388-393.
100. Sulakvelidze A, Alavidze Z, Morris JG (2001). Bacteriophage therapy. Antimicrob Agents Chemother 45: 649-659.
101. Thiel K (2004). Old dogma, new tricks - 21st century phage therapy. Nat Biotechnol 22: 31-36.
102. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027-1031.
103. Walsh CT (2002). Combinatorial biosynthesis of antibiotics: challenges and opportunities. Chembiochem 3: 125-134.
104. Walters WP, Ajay A, Murcko MA (1999). Recognizing molecules with drug-like properties. Curr Opin Chem Biol 3: 384-387.
105. Wang J, Soisson SM, Young K, Shoop W, Kodal S, Galgoci A et al. (2006). Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441: 358-361.
106. Withey S, Cartmell E, Avery LM, Stephenson T (2005). Bacteriophages - potential for application in wastewater treatment processes. Sci Total Environ 339: 1-18.
107. Wright AJ, Wilkowske CJ (1987). The penicillins. Mayo Clin Proc 62: 806-820.
108. Yacoby I, Shamis M, Bar H, Shabat D, Benhar I (2006). Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob Agents Chemother 50: 2087-2097.
109. Yew WW (1999). Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis. Chemotherapy 45 (Suppl 2): 26-33.
110. Yuan Z, White RJ (2006). The evolution of peptide deformylase as a target: contribution of biochemistry, genetics and genomics. Biochem Pharmacol 71: 1042-1047.
111. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J et al. (2004). The glycylcyclines: a comparative review with the tetracyclines. Drugs 64: 63-88.
112. Zuckerman JM (2004). Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 18: 621-649.
113. Zurenko GE, Ford CW, Hutchinson DK, Brickner SJ, Barbachyn MR (1997). Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid. Expert Opin Investig Drugs 6: 151-158.